Related Experiment Video
Updated: Jun 11, 2026
03:25
Simple Continuous Glucose Monitoring in Freely Moving Mice
Published on: February 24, 2023
Early Assessment of Teplizumab Treatment Response Using Continuous Glucose Monitoring
Sari Krepel-Volsky1,2, Merav Gil-Margolis1,2, Keren Smuel-Zilberberg1,2
1The Jesse Z and Sara Lea Shafer Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children's Medical Center of Israel, Petah Tikva, Israel.
Diabetes Technology & Therapeutics
|June 10, 2026
Summary
Continuous glucose monitoring (CGM) reveals varied responses to teplizumab in children with type 1 diabetes. Early CGM data may predict glycemic changes, offering insights into treatment effectiveness.
Area of Science:
- Immunology
- Endocrinology
- Pediatrics
Background:
- Type 1 diabetes (T1D) management requires continuous monitoring of glycemic control.
- Teplizumab is an immunomodulatory agent investigated for its potential impact on T1D progression.
- Understanding treatment effects in real-world settings is crucial for optimizing T1D care.
Purpose of the Study:
- To describe continuous glucose monitoring (CGM) trajectories in children with stage 2 T1D treated with teplizumab.
- To evaluate the utility of CGM metrics in assessing glycemic dynamics during immunomodulatory therapy.
- To explore early indicators of treatment response or disease progression.
Main Methods:
- Longitudinal follow-up of five children with stage 2 T1D receiving teplizumab.
- Utilized continuous glucose monitoring (CGM) to collect data on glycemic variability (GV) and time above 140 mg/dL.
- Analyzed CGM metrics over 8-19 months, correlating with T1D stage and glycated hemoglobin levels.
Main Results:
- Four of five participants maintained stage 2 T1D, showing stabilized or improved GV and reduced time above 140 mg/dL within 3-6 months.
- One participant progressed to stage 3 T1D within 4 months, exhibiting increasing glycemic variability and worsening excursions.
- CGM changes were detectable early and not mirrored by significant glycated hemoglobin shifts.
Conclusions:
- CGM may detect early glycemic dynamics following teplizumab therapy in T1D.
- CGM offers a practical approach for longitudinal monitoring of treatment effects.
- These hypothesis-generating findings require validation in larger pediatric cohorts.
Related Concept Videos
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:29Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...